Objective:To explore clinical curative effect of Shenbai Fuzheng granule combined with bevacizumab+AP regimen(pemetrexed+cisplatin)and its influences on prognosis in non-small cell lung cancer(NSCLC).Methods:70 NSCLC patients were selected as the research subjects and divided into a control group and an observation group according to different treatment plans,with 35 cases in each group.The control group were treated with bevacizumab+AP regimen,and the observation group was treated with a combination of Shenbai Fuzheng granules+bevacizumab+AP regimen for 21 days per cycle,with 2 cycles of treatment for each group.The tumor control[objective response rate(ORR),disease control rate(DCR)],incidence of adverse reactions,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],blood routine[neutrophil to lymphocyte ratio(NLR)],scores of Karnofsky performance status(KPS)and prognosis recurrence were compared between the two groups.Results:After treat-ment,there were no significant difference in ORR and DCR between observation group and control group(P>0.05).The incidence of adverse reactions(bone marrow suppression,gastrointestinal reactions,liver and kidney damage,rash)in observation group was lower than that in control group(P<0.05),levels of NLR,CEA and CA125 were lower than those in control group(P<0.05),KPS score was higher than that in control group(P<0.05),and recurrence rate was lower than that in control group at 1 year after treatment(P<0.05).Conclusion:Shenbai Fuzheng granule combined with targeted chemotherapy regimen has significant toxicity-reducing effect in NSCLC patients,and is conducive to prognosis of patients.